



Scott A. Bauer  
Department Leader  
Regulatory Affairs  
Palo Verde Nuclear  
Generating Station

**10 CFR 26.71(d)**

Tel: 623/393-5978  
Fax: 623/393-5442  
e-mail: sbauer@apsc.com

Mail Station 7636  
P.O. Box 52034  
Phoenix, AZ 85072-2034

102-04601-SAB/TNW/CJJ  
August 29, 2001

U. S. Nuclear Regulatory Commission  
ATTN: Document Control Desk  
Mail Station P1-37  
Washington, DC 20555-0001

Dear Sirs:

**Subject: Palo Verde Nuclear Generating Station (PVNGS)  
Units 1, 2, & 3  
Docket Nos. STN 50-528/529/530  
Fitness-For-Duty Program Semiannual Performance Report**

Pursuant to 10 CFR 26.71(d), Arizona Public Service Company hereby provides, as an enclosure to this letter, the Fitness-For-Duty Program Semiannual Performance Report for the reporting period of January 1, 2001 through June 30, 2001.

No commitments are being made to the NRC by this letter. Should you have any questions, please contact Thomas N. Weber at (623) 393-5764.

Sincerely,

SAB/TNW/CJJ/kg

Enclosure

cc: E. W. Merschoff (all w/enclosure)  
L. R. Wharton  
J. M. Moorman

A021

ENCLOSURE

ARIZONA PUBLIC SERVICE COMPANY

FITNESS-FOR-DUTY PROGRAM

SEMIANNUAL PERFORMANCE REPORT

JANUARY 1, 2001 THROUGH JUNE 30, 2001

SEMIANNUAL PERFORMANCE REPORT

January 1, 2001 - June 30, 2001

PREPARED BY:

William G. Thomack II

William G. Thomack II 8-1-01  
Signature Date

APPROVED BY:

Michael V. Priebe

Michael V. Priebe 8-7-01  
Signature Date

REVIEWED BY:

David N. Heler

David N. Heler 8/2/01  
Signature Date

**Introduction**

The Arizona Public Service Company (APS) Fitness-for-Duty (FFD) Program continues to remain successful in its mission to maintain a drug-free workplace. During this reporting period, APS conducted 1236 tests. Of these, 622 were administered on a random basis. An equivalent annual testing rate of 51.3 percent was achieved during this reporting period.

APS experienced two confirmed positive random drug and alcohol tests during this reporting period. Therefore, the percentage of confirmed positive random drug and alcohol tests for this period is 0.3 percent.

**Analysis of Program Results**

The confirmed positive drug and alcohol test results for this reporting period by type of test and type of drug are summarized in Table 1 and 2 respectively and are discussed below.

**Pre-Access Testing:**

|              |   |                          |
|--------------|---|--------------------------|
| Amphetamines | 2 |                          |
| Cocaine      | 1 |                          |
| Total        | 3 | confirmed positive tests |

Comments: APS tested a total of 518 individuals under the Pre-Access Testing category during this reporting period. Three individuals tested positive. Two of the individuals were contractors and site access was denied and they were released to their employer. The third individual was an APS employee. The employee's site access was denied and the individual was required to enter an intensive outpatient chemical dependency treatment program. The employee has regained site access and has been placed in a follow-up testing program. Protected area access will be determined based upon compliance with the treatment program and a demonstration of trustworthiness and reliability.

**For Cause Testing:**

|         |   |                          |
|---------|---|--------------------------|
| Refusal | 2 |                          |
| Total   | 2 | confirmed positive tests |

Comments: APS tested a total of 11 individuals under the For Cause Testing category during this reporting period. For Cause testing includes: behavior observation, post accident, suspected adulteration of specimens, or an odor of alcohol beverage on an individual. Two contract individuals refused testing and therefore the tests were considered positive. The individuals' site access was suspended and the individuals were released to their employers.

**Random:**

|              |   |                          |
|--------------|---|--------------------------|
| THC          | 1 |                          |
| Amphetamines | 1 |                          |
| Total        | 2 | confirmed positive tests |

Comments: APS tested a total of 622 individuals under the Random Testing category during this reporting period. This constitutes an annual testing rate of 51.3 percent. One contract individual tested positive. The individual's site access was suspended and he was released to his employer. The second individual testing positive was an APS employee. The employee's site access was suspended and he was required to enter an intensive outpatient chemical dependency treatment program. The employee has regained site access and was placed in a follow-up testing program. Protected area access will be determined based upon compliance with the treatment program and a demonstration of trustworthiness and reliability.

**Follow-up Testing:**

|              |   |                                |
|--------------|---|--------------------------------|
| Amphetamines | 1 |                                |
| Total        | 1 | confirmed positive test result |

Comments: APS conducted a total of 57 tests under the Follow-Up Program during this reporting period. The individual registering the positive test was a contract employee. The individual's site access was suspended and she was released to her employer.

**Other Testing:**

Comments: APS conducted a total of 28 tests under this category. All tests were in the category of pre-employment. There were no positive results in this category.

**Reportable Events**

There were no reportable events during this reporting period.

**Fitness for Duty Program  
Performance Data  
Personnel Subject to 10 CFR 26**

|  |                          |                 |          |
|--|--------------------------|-----------------|----------|
| <b>Arizona Public Service Company</b>                        | <b>June 30, 2001</b>     |                 |          |
| Company  | 6 months ending          |                 |          |
| <b>Palo Verde Nuclear Generating Station (PVNGS)</b>         |                          |                 |          |
| Location   |                          |                 |          |
| <b>Michael V. Priebe</b>                                     | <b>(623) 393-3228</b>    |                 |          |
| Contact Name   | Phone(include area code) |                 |          |
| Cutoffs: Screen/Confirmation (ng/ml) Appendix A to 10 CFR 26 |                          |                 |          |
| Marijuana  | 50/15                    | Amphetamines    | 1000/500 |
| Cocaine  | 300/150                  | Phencyclidine   | 25/25    |
| Opiates  | 300/300                  | Alcohol (% BAC) | 0.04%    |

| Testing Results                       |                   | Licensee Employees |            | Long-Term Contractor Personnel |            | Short-Term Contractor Personnel |            |
|---------------------------------------|-------------------|--------------------|------------|--------------------------------|------------|---------------------------------|------------|
| Average Number with Unescorted Access |                   | 2048               |            | NA                             |            | 375                             |            |
| Categories                            |                   | # Tested           | # Positive | # Tested                       | # Positive | # Tested                        | # Positive |
| Pre- Access                           |                   | 78                 | 1          | NA                             | NA         | 440                             | 2          |
| <b>For Cause</b>                      | Post accident     | 1                  | 0          | NA                             | NA         | 3                               | 1          |
|                                       | Observed behavior | 4                  | 0          | NA                             | NA         | 3                               | 1          |
| Random                                |                   | 525                | 1          | NA                             | NA         | 97                              | 1          |
| Follow-Up                             |                   | 34                 | 0          | NA                             | NA         | 23                              | 1          |
| Other                                 |                   | 28                 | 0          | NA                             | NA         | 0                               | 0          |
| <b>Total</b>                          |                   | <b>670</b>         | <b>2</b>   | <b>NA</b>                      | <b>NA</b>  | <b>566</b>                      | <b>6</b>   |

### **Breakdown of Confirmed Positive Tests for Specific Substances**

|                        | <b>Marijuana</b> | <b>Cocaine</b> | <b>Opiates</b> | <b>Ampheta-<br/>mines</b> | <b>Phency-<br/>clidine</b> | <b>Alcohol</b> | <b>Refusal<br/>to Test</b> | <b>Total</b> |
|------------------------|------------------|----------------|----------------|---------------------------|----------------------------|----------------|----------------------------|--------------|
| Licensee Employees     | 0                | 0              | 0              | 2                         | 0                          | 0              | 0                          | 2            |
| Long-Term Contractors  | 0                | 0              | 0              | 0                         | 0                          | 0              | 0                          | 0            |
| Short-Term Contractors | 1                | 1              | 0              | 2                         | 0                          | 0              | 2                          | 6            |
| <b>Total</b>           | <b>1</b>         | <b>1</b>       | <b>0</b>       | <b>4</b>                  | <b>0</b>                   | <b>0</b>       | <b>2</b>                   | <b>8</b>     |

### **Additional Information Required by 10 CFR 26.71 (d)**

Specimens screening positive for marijuana at 50 ng/ml: 2  
Specimens screening positive for marijuana at 100 ng/ml: 1

These numbers include blind specimens sent to offsite lab for testing.